Telmisartan,
does it really help with Prevention of myocardial infarction, stroke, and cardiovascular death in high-risk patients?
research showsTelmisartan is rated C because direct superiority over placebo has not been established in high-risk cardiovascular patients. ONTARGET (2008 NEJM) showed only noninferiority to ramipril, RR 1.01 (95% CI 0.94 to 1.09), and was not placebo-controlled. The placebo-controlled TRANSCEND trial (2008 Lancet; 5,926 participants) failed its primary endpoint, HR 0.92 (95% CI 0.81 to 1.05), P=.216.
ads claimIt is misleading to equate blood-pressure lowering with proven superiority for preventing myocardial infarction or stroke, or to claim that telmisartan is better than ramipril. The evidence supports noninferiority to ramipril and only a limited placebo-controlled signal in ACE-inhibitor-intolerant patients.
Useful facts when choosing a product
- The telmisartan target dose in ONTARGET and TRANSCEND was 80 mg once daily.
- Combining an ACE inhibitor with an ARB did not improve events in ONTARGET and increased hypotension, syncope, renal dysfunction, and hyperkalemia, so it is generally avoided.
- Renal function and potassium require monitoring, and pregnancy is a contraindication because of fetal harm.
What the research actually shows
ONTARGET randomly assigned 25,620 patients with vascular disease or diabetes with end-organ damage to ramipril, telmisartan, or both under double masking. The relevant intention-to-treat primary analysis included 8,542 telmisartan and 8,576 ramipril participants, totaling 17,118; noninferiority for the primary composite succeeded with P=.004. Combination therapy added harm without benefit. TRANSCEND included all 5,926 randomized ACE-inhibitor-intolerant participants in its intention-to-treat analysis; the placebo-controlled primary endpoint was 15.7% versus 17.0%, HR 0.92 (95% CI 0.81 to 1.05), P=.216, and failed. Boehringer Ingelheim funded both pivotal trials.
Why this is classified as C (58)
ONTARGET showed only noninferiority to ramipril, RR 1.01 (95% CI 0.94 to 1.09), and was not placebo-controlled. The placebo-controlled TRANSCEND primary endpoint failed in 5,926 participants, HR 0.92 (95% CI 0.81 to 1.05), P=.216, leaving no direct superiority evidence and capping the result at C with 58 points under rule ①-ⓑ. Boehringer Ingelheim funded both trials.
Counterpoint. Telmisartan can be a clinically useful alternative when cough or angioedema prevents ACE-inhibitor use. Selection should incorporate blood pressure, renal function, potassium, and comorbidities.
Rejudgment record. Cross-check applied — ONTARGET showed only noninferiority to ramipril, RR 1.01 (95% CI 0.94 to 1.09), and was not placebo-controlled; the TRANSCEND placebo-controlled primary endpoint failed in 5,926 participants, HR 0.92 (95% CI 0.81 to 1.05), P=.216, so direct superiority is absent and rule ①-ⓑ caps the result at C; Boehringer Ingelheim funded both trials
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Major cardiovascular-event prevention comparable to ramipril | C | Prespecified noninferiority succeeded in the 17,118-participant ONTARGET intention-to-treat comparison. |
| Prevention of major cardiovascular events versus placebo in ACE-inhibitor-intolerant patients | D | The prespecified primary endpoint failed with P=.216 in all 5,926 TRANSCEND participants. |
| Prevention of the three-component composite of cardiovascular death, myocardial infarction, and stroke | C | The TRANSCEND secondary endpoint was nominally favorable but had P=.068 after multiplicity adjustment. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| ONTARGET Investigators. 2008 | Multinational randomized double-blind active-controlled noninferiority trial | 17,118 | Research grant from Boehringer Ingelheim, with additional individual support from the Heart and Stroke Foundation of Ontario and Canadian Institutes of Health Research | Noninferiority to ramipril for the primary composite of cardiovascular death, myocardial infarction, stroke, or heart-failure hospitalization | 16.7% versus 16.5%, RR 1.01 (95% CI 0.94 to 1.09), noninferiority P=.004, so the primary endpoint succeeded. | Key large active-comparator clinical-event evidence |
| TRANSCEND Investigators. 2008 | Multinational randomized double-blind placebo-controlled superiority trial | 5,926 | Manufacturer funding from Boehringer Ingelheim | Primary composite of cardiovascular death, myocardial infarction, stroke, or heart-failure hospitalization | 15.7% versus 17.0%, HR 0.92 (95% CI 0.81 to 1.05), P=.216, so the primary endpoint failed. | Key conflicting placebo-controlled evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Telmisartan x prevention of major cardiovascular events in high-risk patients — Evidence Grade C·58. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/telmisartan-major-cardiovascular-event-prevention-high-risk/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.